Tamborlane WV, et al. - The intent of the authors was to determine the dose of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in pediatric patients with type 2 diabetes (T2D). The findings revealed that linagliptin was well tolerated and induced dose-dependent DPP-4 inhibition that was accompanied by corresponding reductions in HbA1c and fasting plasma glucose (FPG) levels in young people with T2D. Consistent results were yielded with the clinical efficacy and safety profile that was reported for linagliptin in adult patients with T2D, favoring linagliptin 5 mg over 1 mg.